ReviewF1000prime reports2014
The treatment of idiopathic pulmonary fibrosis.
Review in F1000prime reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 57 citations in OpenAlex.
- Inflammatory Effects and Regulatory Mechanisms of Chitinase-3-like-1 in Multiple Human Body Systems: A Comprehensive Review.International journal of molecular sciences · 2024Review
- The Role of Nrf2 in Pulmonary Fibrosis: Molecular Mechanisms and Treatment Approaches.Antioxidants (Basel, Switzerland) · 2022Review
- CRTH2 Mediates Profibrotic Macrophage Differentiation and Promotes Lung Fibrosis.American journal of respiratory cell and molecular biology · 2022Article
- Functions and clinical significance of mechanical tumor microenvironment: cancer cell sensing, mechanobiology and metastasis.Cancer communications (London, England) · 2022Review
- Metabolic requirements of pulmonary fibrosis: role of fibroblast metabolism.The FEBS journal · 2021Review
- TGF-β Promotes Metabolic Reprogramming in Lung Fibroblasts via mTORC1-dependent ATF4 Activation.American journal of respiratory cell and molecular biology · 2020Article
- Glutamine Metabolism Is Required for Collagen Protein Synthesis in Lung Fibroblasts.American journal of respiratory cell and molecular biology · 2019Article
- Effect of dermatan sulphate on a C57-mouse model of pulmonary fibrosis.The Journal of international medical research · 2019Article
- Hydrogel-based delivery of Il-10 improves treatment of bleomycin-induced lung fibrosis in mice.Biomaterials · 2019Article
- Absence of β6 Integrin Reduces Influenza Disease Severity in Highly Susceptible Obese Mice.Journal of virology · 2019Article
- Inhibition of Phosphoglycerate Dehydrogenase Attenuates Bleomycin-induced Pulmonary Fibrosis.American journal of respiratory cell and molecular biology · 2018Article
- The pronounced high expression of discoidin domain receptor 2 in human interstitial lung diseases.ERJ open research · 2018Article
- Angiotensin-converting enzyme defines matrikine-regulated inflammation and fibrosis.JCI insight · 2017Article
- Pathway‑based detection of idiopathic pulmonary fibrosis at an early stage.Molecular medicine reports · 2017Article
- The Role of Transforming Growth Factor Beta-1 in the Progression of HIV/AIDS and Development of Non-AIDS-Defining Fibrotic Disorders.Frontiers in immunology · 2017Review
- Triazole RGD antagonist reverts TGFβ1-induced endothelial-to-mesenchymal transition in endothelial precursor cells.Molecular and cellular biochemistry · 2017Article
- Recent advances in managing idiopathic pulmonary fibrosis.F1000Research · 2017Review
- Increased Cellular NADTuberculosis and respiratory diseases · 2016Article
- Lung Pericytes and Resident Fibroblasts: Busy Multitaskers.The American journal of pathology · 2016Review
- Precision medicine in idiopathic pulmonary fibrosis.QJM : monthly journal of the Association of Physicians · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Idiopathic pulmonary fibrosis (IPF) is a progressive and invariably fatal disease with a median survival of less than three years from diagnosis. The last decade has seen an exponential increase in clinical trial activity in IPF and this in turn has led to important developments in the treatment of this terrible disease. Previous therapeutic approaches based around regimens including corticosteroids and azathioprine have, when tested in randomized clinical trials, been shown to be harmful in IPF. By contrast, compounds with anti-fibrotic actions have been shown to be beneficial. Subsequently, the novel anti-fibrotic agent pirfenidone has, in many parts of the world, become the first treatment ever to be licensed for use in IPF. This exciting development, coupled with ongoing clinical trials of a range of other novel compounds, is bringing hope to patients and their clinicians and raises the prospect that, in the future, it may become possible to successfully arrest the development of progressive scarring in IPF.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.